ReviewFrontiers in cell and developmental biology2026
Targeting tubular epithelial cell metabolism to halt renal fibrosis: current evidence and future directions.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal fibrosis is a common pathological endpoint of chronic kidney disease, characterized by excessive deposition of extracellular matrix and loss of functional nephrons. Emerging evidence highlights that profound metabolic reprogramming is a hallmark and a fundamental driver of renal fibrosis. Alterations in the central metabolic pathways, including glycolysis, mitochondrial dysfunction and lipid metabolism in tubular epithelial cells promote tubular epithelial cell dysfunction and sustain a pro-fibrotic inflammatory microenvironment. Besides, the metabolic microenvironment, particularly characterized by hypoxia and oxidative stress, plays a critical role in the pathogenesis and progression of renal fibrosis, and targeting the metabolic microenvironment has also emerged as a promising anti-fibrotic strategy. In this review, we summarized the current knowledge and explored the potential of targeting metabolic enzymes or signaling pathways involved in key metabolic pathways may represent a promising strategy to attenuate renal fibrosis. Furthermore, we discussed the contribution of the metabolic microenvironment, including hypoxia and oxidative stress, to the pathogenesis of renal fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.